Cantor Fitzgerald’s Adverum Biotechnologies ADVM Stock Holding History

Cantor Fitzgerald’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,446	Closed	-$67.5K	–	463
2025 Q1	$67.5K	Hold	15,446	–	–	﹤0.01%	249
2024 Q4	$72.1K	Hold	15,446	–	–	﹤0.01%	218
2024 Q3	$108K	Hold	15,446	–	–	﹤0.01%	151
2024 Q2	$106K	Hold	15,446	–	–	0.02%	161
2024 Q1	$218K	Sell	15,446 -370	-2%	-$5.63K	0.05%	137
2023 Q4	$119K	Sell	15,816 -190	-1%	-$1.73K	0.02%	150
2023 Q3	$240K	Sell	16,006 -278	-2%	-$4.99K	0.01%	418
2023 Q2	$259K	Buy	16,284 +2,000	+14%	+$21K	0.01%	457
2023 Q1	$102K	Buy	14,284 +784	+6%	+$5.54K	﹤0.01%	571
2022 Q4	$78K	Buy	13,500 +11,500	+575%	+$87.2K	﹤0.01%	610
2022 Q3	$19K	Buy	+2,000	New	+$26.3K	﹤0.01%	689

Other funds holding ADVM

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

PWA

Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cantor Fitzgerald's ADVM Position: Q2 2025 in Review

Cantor Fitzgerald sold out of Adverum Biotechnologies (ADVM) in Q2 2025, closing a stake of 15,446 shares — an estimated $67.5K sold.

Cantor Fitzgerald first reported a position in ADVM in Q3 2022 and held it in 11 quarters. The position peaked at $259K in Q2 2023. 58 funds tracked by Wall St. Rank hold ADVM as of Q2 2025.

Cantor Fitzgerald reported no remaining Adverum Biotechnologies position as of Q2 2025 after selling out during the quarter.
Cantor Fitzgerald sold 15,446 Adverum Biotechnologies shares in Q2 2025, an estimated $67.5K.
Cantor Fitzgerald first reported a position in Adverum Biotechnologies in Q3 2022 and held it in 11 quarters.
Cantor Fitzgerald's Adverum Biotechnologies position peaked at $259K in Q2 2023.
58 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2025.

Based on Cantor Fitzgerald's 13F filing for Q2 2025, filed 14 Aug 2025.